RT Journal Article
SR Electronic
T1 High prevalence and risk factors of transmission of hepatitis delta virus in pregnant women in the Center Region of Cameroon
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.08.23291160
DO 10.1101/2023.06.08.23291160
A1 Ondigui, Juliette-Laure Ndzie
A1 Goumkwa, Nadège Mafopa
A1 Lobe, Cindy
A1 Wandji, Brigitte
A1 Awoumou, Patrick
A1 Djivida, Prisca Voussou
A1 Peyonga, Puinta
A1 Atah, Solange Manju
A1 Verbe, Vivian
A1 Simo, Rachel Kamgaing
A1 Moudourou, Sylvie Agnès
A1 Gutierrez, Ana
A1 Garcia, Rosi
A1 Fernandez, Isabelle
A1 Riwom Essama, Sara Honorine
A1 Mbu, Robinson
A1 Torimiro, Judith
YR 2023
UL http://medrxiv.org/content/early/2023/06/12/2023.06.08.23291160.abstract
AB Background Hepatitis B virus (HBV) and hepatitis delta virus (HDV) co-infection has been described as the most severe form of viral hepatitis, and both can be co-transmitted from mother-to-child. A seroprevalence of 4.0% of HDV infection was reported in pregnant women in Yaoundé, and 11.9% in the general population in Cameroon. Our objective was to describe the rate of HDV infection in pregnant women and to determine risk factors associated with mother-to-child transmission of HDV.Materials and Methods A cross-sectional, descriptive study was conducted from January 2019 to July 2022 among pregnant women attending antenatal contacts in seven health structures in the Centre Region of Cameroon. A consecutive sampling (non-probability sampling) was used to select only women of age over 21 years, who gave a written informed consent. Following an informed consent, an open-ended questionnaire was used for a Knowledge, Attitude and Practice (KAP) survey of these women, and their blood specimens collected and were screened for HBsAg, anti-HIV and anti-HCV antibodies by rapid tests and ELISA. HBsAg-positive samples were further screened for HBeAg, anti-HDV, anti-HBs, and anti HBc antibodies by ELISA, and plasma HDV RNA load measured by RT-qPCR.Results Of 1992 pregnant women, a rate of 6.7% of HBsAg (134/1992) with highest rate in the rural areas, and 3.9% of hepatitis vaccination rate were recorded. Of 134, 44 (32.3%) were anti-HDV antibody-positive, and 47.6% had detectable RNA viraemia. Two women of 44 anti-HDV-positive cases (4.5%) were co-infected with HBV and HCV, while 5 (11.4%) with HIV and HBV. Multiple deliveries, the presence of tattoos and/or scarifications were significantly statistically associated with the presence of anti-HDV antibodies. Of note, 80% of women with negative HBeAg and positive anti-HBe serological profile, had plasma HDV RNA load of more than log 3.25 (>10.000 copies/ml).Conclusion These results show an intermediate rate of HDV infection among pregnant women with high level of HDV RNA viremia, which suggest an increased risk of vertical and horizontal co-transmission of HDV.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received specific funding from PI Institution and Award to PI.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The National Ethics Committee for Human Health Research in Cameroon (N° 2018/06/1150/L/CNERSH/SP)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.